ScreenerHero

DYAIDyadic International, Inc.

NAS · US · Healthcare · Biotechnology · dyadic.com
0.6900USD-6.62%Mkt Cap: 27.64M $P/E: —

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Produ…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap27.64M $
Enterprise Value27.44M $
Revenue (TTM)3.80M $
Gross Profit-1.09M $
Net Income (TTM)-7.36M $
Revenue/Share0.1060 USD
Last Price0.6900 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.19
PEG—
EV/EBITDA—
EV/Revenue7.22
P/S7.38
P/B-10.61
EPS (TTM)-0.21
EPS (Forward)-0.32
52W Range
0.65004% of range1.600
52W High1.600 USD
52W Low0.6500 USD
Profitability
Gross Margin-88.25%
Oper. Margin-212.82%
EBITDA Margin0.00%
Profit Margin-597.63%
ROE-597.58%
ROA-74.05%
Growth
Revenue Growth-0.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.70M $
CapEx (TTM)—
FCF Margin-126.48%
FCF Yield-17.40%
Net Debt1.93M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity4.11
Current Ratio1.65
Quick Ratio1.14
Book Value/Sh-0.0660 USD
Cash/Share0.0850 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.500 USD
Upside (mean)+697.1%
Target Range4.000 USD – 7.000 USD
$4.000+697.1% to mean$7.000
# Analysts2
Ownership
Shares Out.40.06M
Float32.33M
Insiders22.90%
Institutions12.32%
Short Interest
Short Ratio0.2d
Short % Float0.17%
Short % Out.0.15%
Shares Short52.98K
Short (prev mo.)174.71K
Technical
SMA 500.9660 (-28.6%)
SMA 2000.8810 (-21.7%)
Beta1.02
S&P 52W Chg18.16%
Avg Vol (30d)221.57K
Avg Vol (10d)197.40K
Technical Indicators
RSI (14)31.4
MACD-0.0781
MACD Signal-0.0334
MACD Hist.-0.0447
BB Upper1.286 USD
BB Middle0.9790 USD
BB Lower0.6722 USD
BB Width62.68%
ATR (14)0.1099 USD
Vol Ratio (20d)0.57x